Mutant prevention concentration as a strategy to minimize antimicrobial resistance: A timely concept but will its acceptance be too late?

Therapy

Volumn 2, Issue 1, 2005, Pages 61-66

  Hansen, Glen T ^a   Blondeau, Joseph M ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BACTERIUM MUTANT; COLONY FORMING UNIT; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 13444304418     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.1.61     Document Type: Article

References (37)

1. Gould JC: The laboratory control of antibiotic therapy Br. Med. Bull. 16, 29-34 (1960).
2. Dong Y, Zhao X, Domagala J, Drlica K: Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 1756-1758 (1999).
3. Blondeau J, Zhao X, Hansen GT, Drlica K: Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 433-438 (2001).
4. Blondeau JM, Hansen G, Metzler KL, Hedlin P: The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemo. 16, 1-19 (2004).
5. Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE: Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia Clin. Infect. Dis. 37, 376-381 (2003).
6. Chen D MA, de Azavedo JC, Low DE.: The Canadian Bacterial Surveillance Network: Decreased susceptibility of Streptococcus pneumonaie to fluoroquinolones in Canada. N Engl. J. Med. 341, 233-239 (1999).
7. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N. Engl. J. Med 346, 747-750 (2002).
8. Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ: Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy J. Inject. Dis. 184, 794-798 (2001).
9. Blondeau JM, Hansen G, Metzler KL, Borsos S, Chau J: Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin. Royal Society of Medicine Press 15-26. (2002).
10. Blondeau JM, Borsos S, Hesje C, Blondeau DL. The killing of multidrug resistant Streptococcus pneumoniae (MDRSP) by Gatifloxacin (GA), Gemifloxacin (GM), Levofloxacin (Lfx) and Moxifloxacin (Mfx) over a range of bacterial inoculums using 2 different drug concentrations. World Conference on Magic Bullets - To Celebrate Paul Ehrlich's 150th Birthday, Nurnberg, Germany, September 9-11, 2004. Abstract #629.
11. Blondeau JM, Borsos S, Hesje C, Tillotson G. The killing of multidrug resistant Streptococcus pneumoniae (MDRSP) by gemifloxacin (GM) and levofloxacin (Lfx) over a range of bacterial inocula using 2 different drug concentrations. Resistant gram-positive infections, Berlin, December 10-12, 2004. Abstract #5, page 61.
12. Blondeau JM, Borsos S: Application of the resistance prevention concentration (RPC) and minimal inhibitory concentration (MIC) of clinical isolates of Streptococcus pneumoniae (SP) against macrolides. In: World Conference on Magic Bullets, Nurnberg, Germany (2004).
13. Baquero F: Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study Antimicrobial Agents and Chemotherapy 38(Suppl. A), 117-132 (1996).
14. Johnson AP: Antibiotic resistance among clinically important gram-positive bacteria in the UK J. Hospital Infection 40, 17-26 (1998).
15. Hoban D, Waites K, Felmingham D: Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study Diagn. Microbiol. Infect. Dis. 45, 251-259 (2003).
16. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against staphylococcus aureus. Antimicrob. Agents Chemother. 47(5), 1604-1613 (2003).
17. Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob. Chemother. 52(4), 616-622 (2003).
18. Croisier D, Etienne M, Piroth L et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J. Antimicrob. Chemother. 54, 640-647 (2004).
19. Doern GV, Brown SD: Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01 J. Infect. 48, 56-65 (2004).
20. Allen GP: The Mutant Prevention Concentration (MPC): A Review. J. Infect. Dis. Pharmacother. 6, 27-47 (2003).
21. Liu Q SS: PAP: detection of ultra rare mutations depends on P* oligonucleotides: "sleeping beauties" awakened by the kiss of pyrophosphorolysis Human Mutations 23, 426-436 (2004).
22. Liu Q SS: Pyrophosphorolysis-activatable oligonucleotides may facilitate detection of rare alleles, mutation scanning and analysis of chromatin structures. Nucleic Acids Research 15, 598-604. (2002).
23. Liu Q SS: Pyrophosphorolysis-activated polymerization (PAP): application to allele-specific amplification. Biotechniques 29, 1072-1076. (2000).
24. Hansen GT BJ: Mutant Prevention Concentration (MPC) for quinolones an non-quinolone antimicrobial agents against clinical isolates of Pseudomonas aeruginosa and the effect of antibiotic combinations, in 22nd International Congress of Chemotherpay, Amsterdam, NL (2001).
25. Zhao X, Drlica K: Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window J. Infect.Dis. 185, 561-565 (2002).
26. Lu T, Zhao X, Li Y, Hansen G, Blondeau J, Drlica K: Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium. smegmatis and Staphylococcus aureus J. Antimicrob. Chemother. 52, 61-64 (2003).
27. Metzler K, Hansen G, Hedlin P, Harding E, Drlica K, Blondeau JM: Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 24, 161-167 (2004).
28. Drlica K: Controlling Antibioitc Resistance: strategies based on the mutant selection window, in Reemrgence of established pathogens in the 21st century. Drlica F (Ed.), Plenum publishers, NY, USA, 295-331 (2003).
29. Zhao X Z: Clarification of the MPC and the mutant selection window J. Antimicrobial Chemother. 52, 731 (2003).
30. Livermore DM: Overstretching the mutant prevention concentration. J. Antimicrob. Chemother. 52, 732 (2003).
31. Phillips I, Culebras E, Moreno F, Baquero F: Induction of the SOS response by new 4-quinolones J. Antimicrob. Chemother. 20, 631-638 (1987).
32. Piddock L WR. Induction of the SOS response in Escherichia coli by 4-quinolone antimicrobial agents FEMS Microbiology Letters 41, 289-294 (1987).
33. Phillips I: Bacterial mutagenicity and the 4-quinolones J. Antimicrob. Chemother. 20, 771-773 (1987).
34. Etienne M, Croisier D, Charles PE et al: Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits J. Infect. Dis. 190, 1472-1475 (2004).
35. Gillespie SH VL, Dickens A.: Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microbial Drug Resistance 8, 79-84 (2002).
36. Blot M HB, Monnet G.: The Tn5 bleomycin resistance gene confers improved survival and growth advantage on Escherichia coli. Molecular Genetics 242, 595-601 (1994).
37. Smith H, Nichol KA, Hoban DJ, Zhanel GG: Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother. 51, 1323-1325 (2003).